Status:
COMPLETED
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18-130 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients wi...
Eligibility Criteria
Inclusion
- Written Informed Consent
- Carcinoma of the colon or rectum
- One or more measurable lesions
Exclusion
- Adjuvant/neoadjuvant therapy within 6-12 months of study entry
- Untreated unstable brain or meningeal metastases
- Specific laboratory ranges
- Specific cardiovascular problems
- Participation in other trials within 30 days
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
1254 Patients enrolled
Trial Details
Trial ID
NCT00399035
Start Date
November 1 2006
End Date
August 1 2016
Last Update
December 28 2016
Active Locations (90)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Buenos Aires, Argentina
2
Research Site
Capital Federal, Argentina
3
Research Site
Ciudad de Buenos Aires, Argentina
4
Research Site
Córdoba, Argentina